COO of Bachem AG

From compliance to strategy: ESG in pharma supply chain design

More than a tool for risk management and compliance, ESG is becoming a driver of operational resilience, supply security and long-term competitive advantage.

As geopolitical uncertainty, supply chain disruption, and demand for increasingly complex therapies continue to rise, pharmaceutical manufacturers are placing greater emphasis on resilient, transparent and sustainable supply chains.

For CDMOs and their pharmaceutical partners, sustainability is no longer a standalone objective. It is increasingly embedded in strategic decision-making, shaping supplier selection, manufacturing technologies, data governance and long-term investment across the value chain.

ESG starts with stronger partnerships

The pharmaceutical supply chain is inherently collaborative. APIs, raw materials, specialist technologies and analytical expertise often pass through multiple organizations before reaching patients.

As peptide and oligonucleotide manufacturing become more specialized, strategic partnerships are increasingly essential, providing access to expertise in process development, analytics, regulatory support and long-term supply chain planning.

The same is true for sustainability. A significant share of pharmaceutical emissions sits within upstream supply chains, making supplier engagement critical. As a result, supplier codes of conduct and independent frameworks such as EcoVadis and the Science Based Targets initiative (SBTi) are playing an increasingly important role in driving transparency, accountability and continuous improvement across the value chain.

Manufacturing innovation is becoming an ESG strategy

Manufacturing innovation has become a strategic imperative for companies seeking to simultaneously advance sustainability, improve productivity, and maintain competitive advantage. Automation, digitalization, and process technologies such as continuous chromatography, tag-assisted synthesis, and enzymatic ligation are enhancing process efficiency while reducing solvent consumption, waste generation, and overall Process Mass Intensity (PMI). At the same time, advances in selective chemistries are improving yields and minimizing resource inputs, demonstrating how innovation can deliver both business and environmental value.

While efforts to replace hazardous materials and adopt greener solvents remain important, the greater opportunity lies in rethinking the underlying chemistry itself. Emerging technologies enable more selective and efficient synthetic pathways that can reduce or eliminate the need for certain problematic reagents, solvents, and process steps altogether. Rather than incrementally improving existing manufacturing approaches, innovation is increasingly allowing sustainability to be designed into the process from the outset. In this way, sustainability is evolving from an operational consideration into a fundamental principle of process and technology development.

Transparency is becoming a competitive advantage

As ESG expectations rise, pharmaceutical companies need greater visibility across increasingly complex supply chains. Regulators, investors and customers want to understand not only where materials originate, but how they are manufactured, transported and governed.

Meeting these expectations requires robust digital infrastructure, from integrated supplier management and quality systems to advanced analytics that enable traceability, compliance and ESG reporting.

For CDMOs, manufacturing capability alone is no longer enough. Partners increasingly expect transparent sustainability data, reliable reporting and full supply chain visibility to support their own disclosure requirements.

Resilience and ESG are converging

Global disruptions over the past decade have reinforced the strong link between sustainability and resilience. Pandemics, geopolitical tensions, trade restrictions, logistics disruptions, and climate-related events have exposed vulnerabilities across pharmaceutical supply chains, underscoring the importance of maintaining operational continuity.

As a result, organizations are re-evaluating supplier networks, regional manufacturing footprints, and sourcing strategies to build greater agility and resilience. Increasingly, resilience and ESG are no longer viewed as separate priorities but as interconnected strategic imperatives. Leading companies are integrating both into comprehensive risk and business planning frameworks that strengthen operational performance while supporting long-term sustainability objectives.

Turning ESG strategy into operational reality

As ESG expectations evolve, success depends on turning commitments into measurable action.

At Bachem, this includes a target to reduce absolute Scope 1 and 2 greenhouse gas emissions by 44% by 2030 and engage 67% of suppliers in setting science-based emissions targets. Complementing these goals, initiatives such as the R4 solvent strategy and investments in continuous chromatography and tag-assisted synthesis demonstrate how sustainability can be embedded directly into API manufacturing.

Rather than a standalone reporting exercise, ESG is becoming an integral part of operational excellence, driving environmental performance, efficiency and compliance.

From compliance to commitment

The next phase of ESG in pharmaceutical manufacturing is unlikely to be defined by reporting alone. Demonstrable action and a sustainability mindset will be key.

As supply chains become more complex and sustainability expectations rise, competitive advantage will increasingly depend on how effectively organizations collaborate, share data and drive sustainability across the value chain.

ESG is no longer a separate workstream, it is becoming a core element of supply chain design. Companies that integrate sustainability and resilience into their decision-making will be best positioned to support the next generation of pharmaceutical innovation.